SCHEMBL1102685

SCHEMBL1102685

c1ccc2cc(-c3c4ccccc4c(-c4ccc(-c5ccc(-c6c7ccccc7c(-c7ccc8ccccc8c7)c7ccncc67)cc5)cc4)c4cnccc34)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.51
CYP11B2 P19099 3/20 0.51
CYP17A1 P05093 1/20 0.51
CYP19A1 P11511 1/20 0.51
TDO2 P48775 2/20 0.43
HTR2B P41595 1/20 0.43
HTR5A P47898 1/20 0.43
MAPK10 P53779 6/20 0.43
MAPK9 P45984 5/20 0.43
MAPK8 P45983 3/20 0.43
PRKCZ Q05513 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CCNC P24863 3/20 0.41
CDK8 P49336 3/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102710 0.98 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102895 0.98 CYP11B1 (0.53) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102700 0.97 CYP11B1 (0.53) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102912 0.97 CYP11B1 (0.53) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102697 0.97 CYP11B2 (0.56) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102635 0.97 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102481 0.97 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102788 0.95 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102926 0.95 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1TDO2
SCHEMBL1102774 0.95 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 CYP11B1 836/4885CYP11B2 652/4885CYP17A1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.